Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
From Doge to deal : Is Musk getting back to Trump’s Washington ?
26/09/2025
NCDEX shareholders approve Rs 770 crore preferential issue to fund equity, equity derivatives launch
26/09/2025
Raymond Lifestyle shares slide 4% as Income Tax Department conducts survey at offices and units
26/09/2025
CarTrade shares more than double in 1 year. Elara sees 36% upside, here's why
26/09/2025
